Literature DB >> 16879867

Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression.

Michael Kline1, Kathleen Donovan, Linda Wellik, Christopher Lust, Wendy Jin, Laurie Moon-Tasson, Yuning Xiong, Thomas E Witzig, Shaji Kumar, S Vincent Rajkumar, John A Lust.   

Abstract

Multiple myeloma (MM) is a product of interactions between tumor plasma cells and multiple cell types native to the bone marrow (BM). We have used antibody array technology to examine the proteins produced by BM stromal cells in response to stimulation by BM taken from patients diagnosed with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and MM. We observed increased production of the chemokine IL-8 by stromal cells co-cultured with supernatants from bone marrow cells of patients with active myeloma. IL-8 production is correlated with active disease and is dependent upon IL-1beta and NF-kappaB signaling. Consistent with the pro-angiogenic activity of IL-8, increased BM microvessel density (MVD) correlated with stimulation of stromal cell IL-8 production. In addition, the majority of MM cell lines and MM patient plasma cells were found to express IL-8 receptors CXCR1 and CXCR2. We conclude that stromal cell IL-8 production parallels MM disease activity, is IL-1beta induced, and correlates with bone marrow angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16879867     DOI: 10.1016/j.leukres.2006.06.012

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  24 in total

1.  Bone marrow mast cell density correlates with serum levels of VEGF and CXC chemokines ENA-78 and GRO-α in multiple myeloma.

Authors:  C A Pappa; G Tsirakis; M Devetzoglou; M Zafeiri; R Vyzoukaki; A Androvitsanea; A Xekalou; K Sfiridaki; M G Alexandrakis
Journal:  Tumour Biol       Date:  2014-02-23

2.  Angiogenesis and multiple myeloma.

Authors:  Nicola Giuliani; Paola Storti; Marina Bolzoni; Benedetta Dalla Palma; Sabrina Bonomini
Journal:  Cancer Microenviron       Date:  2011-07-07

Review 3.  Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Authors:  Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti
Journal:  Leuk Lymphoma       Date:  2013-04-11

4.  Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease.

Authors:  Adriana Zingone; Weixin Wang; Meghan Corrigan-Cummins; S Peter Wu; Ryan Plyler; Neha Korde; Mary Kwok; Elisabet E Manasanch; Nishant Tageja; Manisha Bhutani; Marcia Mulquin; Diamond Zuchlinski; Mary Ann Yancey; Mark Roschewski; Yong Zhang; Aldo M Roccaro; Irene M Ghobrial; Katherine R Calvo; Ola Landgren
Journal:  Cytokine       Date:  2014-07-17       Impact factor: 3.861

5.  Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.

Authors:  Yu-Tzu Tai; Betty Y Chang; Sun-Young Kong; Mariateresa Fulciniti; Guang Yang; Yolanda Calle; Yiguo Hu; Jianhong Lin; Jian-Jun Zhao; Antonia Cagnetta; Michele Cea; Michael A Sellitto; Mike Y Zhong; Qiuju Wang; Chirag Acharya; Daniel R Carrasco; Joseph J Buggy; Laurence Elias; Steven P Treon; William Matsui; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2012-06-11       Impact factor: 22.113

6.  miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells.

Authors:  Nicola Amodio; Dina Bellizzi; Marzia Leotta; Lavinia Raimondi; Lavinia Biamonte; Patrizia D'Aquila; Maria Teresa Di Martino; Teresa Calimeri; Marco Rossi; Marta Lionetti; Emanuela Leone; Giuseppe Passarino; Antonino Neri; Antonio Giordano; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Cell Cycle       Date:  2013-09-25       Impact factor: 4.534

7.  The significance of non correlation between interleukin-8 serum levels with bone marrow microvascular density in patients with myeloma multiple.

Authors:  Constantina A Pappa; George Tsirakis; Anna Boula; Aikaterini Sfiridaki; Fotios E Psarakis; Michael G Alexandrakis; Efstathios N Stathopoulos
Journal:  Pathol Oncol Res       Date:  2013-02-28       Impact factor: 3.201

8.  Inhibition of proliferation and induction of apoptosis in multiple myeloma cell lines by CD137 ligand signaling.

Authors:  Charles Gullo; Liang Kai Koh; Wan Lu Pang; Kian Tong Ho; Shi Hao Tan; Herbert Schwarz
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

9.  Platelet factor 4 induces cell apoptosis by inhibition of STAT3 via up-regulation of SOCS3 expression in multiple myeloma.

Authors:  Pei Liang; Suk Hang Cheng; Chi Keung Cheng; Kin Mang Lau; Shek Ying Lin; Eudora Y D Chow; Natalie P H Chan; Rosalina K L Ip; Raymond S M Wong; Margaret H L Ng
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941

10.  Small interfering RNA-mediated CXCR1 or CXCR2 knock-down inhibits melanoma tumor growth and invasion.

Authors:  Seema Singh; Anguraj Sadanandam; Michelle L Varney; Kalyan C Nannuru; Rakesh K Singh
Journal:  Int J Cancer       Date:  2010-01-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.